Study on the efficacy of docetaxel and nedaplatin in treatment of epithelial ovarian cancer
- VernacularTitle:多西他赛联合奈达铂治疗卵巢上皮性癌的疗效分析
- Author:
Lin YANG
;
Huichao SUN
- Publication Type:Journal Article
- Keywords:
epithelial ovarian cancer;
docetaxel;
nedaplatin
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;37(4):79-80,84
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of docetaxel and nedaplatin (NDP)in treatment of patients with epithelial ovarian cancer. Methods 50 cases with epithelial ovarian cancer collected in Shifang People’s Hospital from 2009 January to 2010 January were randomly divided into treatment group and control group,each had 25 cases.Treatment group were given docetaxel and nedaplatin,while control group were given carboplatin. The efficacy and adverse reactions in two groups were observed and compared.Results The recent efficacy in two groups were 76.00% and 52.00%, respectively,and the difference was significant (P <0.05 ).Compared with control group, the incidence of leucopenia was 36.00% and thrombocytopenia was 24.00% in treatment group,there was no significant difference between them.The incidences of nausea,vomiting and alopecia in treatment group were 12.00%,8.00% and 44.00%,which lower than that in control group (40%,28% and 64%),the differences between two groups were all significant(P<0.05 ).The two years survival rates in treatment group was 37.5%,and 28% in control group,there was no significant difference between two groups.Conclusion Docetaxel and nedaplatin has good clinical efficacy in treatment of epithelial ovarian cancer.
